Opioid

Pinnacle Treatment Centers Expands Addiction Treatment Services with the Opening of Canton, Georgia Location

Retrieved on: 
Thursday, August 31, 2023
Employment, Naltrexone, Senior counsel, PTC, Peach, National Association Medical Staff Services, Opioid, Patient, Pinnacle, Methadone, Opioid use disorder, Counselor, Environment, Family therapy, Family, Substance abuse, Hospital

Canton, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Canton, Georgia– 8/31/2023

Key Points: 
  • Canton, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Canton, Georgia– 8/31/2023
    Pinnacle Treatment Centers (PTC) , a leading provider of comprehensive substance abuse treatment services, is pleased to announce the opening of its newest location in Canton, Georgia.
  • With a commitment to delivering personalized and evidence-based care, Pinnacle Treatment Centers aims to make a positive impact on individuals struggling with addiction in the local community.
  • Pinnacle provides underserved communities with affordable, accessible substance abuse treatment and the option of outpatient care.
  • “HealthQwest Canton offers treatment for anyone looking to escape the cycle of Opioid addiction,” says Nicole Habbe, Regional Director for Pinnacle Treatment Centers.

Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program

Retrieved on: 
Thursday, August 31, 2023
State, Employment, Caregiver, Addiction, Private law, Opioid, Workplace, FWC, St. Louis Fed Financial Stress Index, Quality of life, DSM-IV codes, Woman, Cure, RCN, ALKS, Organization, Community, Risk, Council, Recovery, Virtual reality, Self-assessment, Conditional sentence, Ovarian cancer, Trauma, Mental health, Dr. Dobb's Excellence in Programming Award, Commerce, Pharmaceutical industry, Nursing, Residential care, Birth control, Cancer, Alkermes

DUBLIN, Aug. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of the 2023 Alkermes Inspiration Grants® program. Grants were awarded to 11 nonprofit organizations working to address the needs of people living with addiction, serious mental illness or cancer. The selected programs are also focused on addressing unmet needs in historically under-resourced or underrepresented communities with longstanding and widespread health disparities.

Key Points: 
  • – Competitive Grants Program Awards Funding to 11 Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer –
    DUBLIN, Aug. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of the 2023 Alkermes Inspiration Grants® program.
  • This year's recipients have shown the potential, through unique and meaningful ways, to positively impact diverse communities across the United States," said Richard Pops, Chief Executive Officer of Alkermes.
  • For more information on the Alkermes Inspiration Grants program, please visit https://www.alkermes.com/responsibility/alkermes-inspiration-grants .
  • 2023 Grant Recipient Organizations and Programs:
    The 12-24 Club's Fresh Start Cafe Job Training Program offers employment in the Fresh Start Cafe kitchen.

Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program

Retrieved on: 
Thursday, August 31, 2023
State, Employment, Caregiver, Addiction, Private law, Opioid, Workplace, FWC, St. Louis Fed Financial Stress Index, Quality of life, DSM-IV codes, Woman, Cure, RCN, ALKS, Organization, Community, Risk, Council, Recovery, Virtual reality, Self-assessment, Conditional sentence, Ovarian cancer, Trauma, Mental health, Dr. Dobb's Excellence in Programming Award, Commerce, Pharmaceutical industry, Nursing, Residential care, Birth control, Cancer, Alkermes

DUBLIN, Aug. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of the 2023 Alkermes Inspiration Grants® program. Grants were awarded to 11 nonprofit organizations working to address the needs of people living with addiction, serious mental illness or cancer. The selected programs are also focused on addressing unmet needs in historically under-resourced or underrepresented communities with longstanding and widespread health disparities.

Key Points: 
  • – Competitive Grants Program Awards Funding to 11 Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer –
    DUBLIN, Aug. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of the 2023 Alkermes Inspiration Grants® program.
  • This year's recipients have shown the potential, through unique and meaningful ways, to positively impact diverse communities across the United States," said Richard Pops, Chief Executive Officer of Alkermes.
  • For more information on the Alkermes Inspiration Grants program, please visit https://www.alkermes.com/responsibility/alkermes-inspiration-grants .
  • 2023 Grant Recipient Organizations and Programs:
    The 12-24 Club's Fresh Start Cafe Job Training Program offers employment in the Fresh Start Cafe kitchen.

Waismann Method Shines a Light on the Unseen this International Overdose Awareness Day 2023

Retrieved on: 
Wednesday, August 30, 2023
Education, Seed, Friends, Opioid, Opioid use disorder, International Overdose Awareness Day, Community, Drug, Community engagement, Bias, IOAD, Mental health, Pharmaceutical industry, Nursing

Recognized internationally, IOAD fervently works to reduce overdose deaths, honor the lives lost without bias, and provide solace to the mourning relatives and friends.

Key Points: 
  • Recognized internationally, IOAD fervently works to reduce overdose deaths, honor the lives lost without bias, and provide solace to the mourning relatives and friends.
  • This year's pivotal theme, "Recognizing those people who go unseen," underscores the countless unnoticed victims of the opioid epidemic.
  • "In the face of the overwhelming overdose crisis, our daily endeavor at Waismann Method is rooted in providing advanced, medically proven solutions," articulated Clare Waismann.
  • Waismann Method's IOAD 2023 Initiatives:
    Educational Podcasts : Hosting educational podcasts elucidating overdose prevention, the nuances of opioid dependence, and advanced medical-based treatment modalities.

Valiant Behavioural Health Celebrates 5 Years

Retrieved on: 
Wednesday, August 30, 2023
Life, Aftercare, VBH, Heroin, Opioid, Valiant, Patient, System, Mental health, Fentanyl, Counselor, Nursing, Health insurance

OTTAWA, ON, Aug. 30, 2023 /PRNewswire/ -- October 10th marks five years since the opening of Valiant Behavioural Health, an addiction and mental health treatment program based in Ottawa, Ontario. Since opening its doors five years ago, Valiant has been on a mission to make meaningful and lasting changes in the lives of individuals and families in Ottawa by providing unparalleled care to those seeking treatment for mental health and substance use.

Key Points: 
  • OTTAWA, ON, Aug. 30, 2023 /PRNewswire/ -- October 10th marks five years since the opening of Valiant Behavioural Health, an addiction and mental health treatment program based in Ottawa, Ontario.
  • Valiant Behavioural Health approach to treatment has been a successful combination of evidence-based care, a client-centered atmosphere and holistic practices.
  • "At Valiant, we take a comprehensive, holistic approach to substance use and mental health treatment," says Royce Dockrill, Chief Executive Officer of Valiant Behavioural Health.
  • Valiant Behavioural Health is part of the Valiant Recovery brand of treatment centers, one of Canada's leading addiction and mental health treatment providers .

Spark Biomedical Awarded $1.15M Department of Defense Phase II STTR Grant in Partnership with Battelle Memorial Institute

Retrieved on: 
Tuesday, August 29, 2023
Sparrowhawk, Partnership, Headache, Firefighter, Tan, Anxiety, Health care, Sparrow, Quality of life, Woman, First responder, Opioid, Post-traumatic stress disorder, Battelle, Patient, NIDA, Nausea, Emergency department, Injury, FDA, ASR, Mental health, Irritability, PTSD, Substance abuse, Pharmaceutical industry, Nursing, Medical device

In partnership with Battelle, Sparrow Hawk development brings a rapidly deployable, non-invasive, wearable approach to ASR prevention and treatment into the battlefield setting.

Key Points: 
  • In partnership with Battelle, Sparrow Hawk development brings a rapidly deployable, non-invasive, wearable approach to ASR prevention and treatment into the battlefield setting.
  • ASR can result in anxiety, nausea, irritability, dysregulated emotions, poor sleep, poor concentration, cognitive fatigue, and headaches.
  • During Phase I, the team at Spark Biomedical successfully completed critical benchmarks by developing performance parameters and form factors for a revolutionary compact, disposable, cable-free, “all-in-one” wearable tAN device.
  • In Phase II Spark Biomedical and Battelle will focus on:
    Testing the device in a clinical setting to evaluate its efficacy in restoring performance on operationally relevant tasks within a meticulously crafted clinical model of laboratory stress.

Pinnacle Treatment Centers to host Grand Opening celebration for Winchester Treatment Services

Retrieved on: 
Monday, August 28, 2023
Other Health, Hospitals, Health, Pharmaceutical, Managed Care, Parent, Methadone, Pregnancy, OTP, Grief, FDA, MAT, Opioid, Heroin, Senior counsel, Pharmaceutical industry

One of Pinnacle’s 8 opioid treatment programs (OTP) in the state , Winchester Treatment Services provides medication-assisted treatment (MAT), particularly methadone and suboxone, coupled with various methods of counseling and behavioral therapies at the facility.

Key Points: 
  • One of Pinnacle’s 8 opioid treatment programs (OTP) in the state , Winchester Treatment Services provides medication-assisted treatment (MAT), particularly methadone and suboxone, coupled with various methods of counseling and behavioral therapies at the facility.
  • MAT is the gold standard of care for opioid addiction.
  • The FDA-approved medicines work to curb withdrawal symptoms from heroin and pain pill addiction, prevent relapse, and help ease the physical discomfort that accompanies opioid recovery.
  • Individuals needing addiction treatment can call (859) 287-1098 for a free, confidential assessment.

Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder

Retrieved on: 
Monday, August 28, 2023
Research, Mental Health, Neurology, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Ketan, Pharma, Wayne State University, Opioid, Public, Initiative, ADHD, DSM-IV codes, Opioid use disorder, OUD, FQ, Heroin, Bangladesh Technical Education Board, Pain, Cocaine, NOP, National Institute on Drug Abuse, MOP, NIDA, Pain management, Drug, Schedule 2, FDA, NIH, Disease, Pharmaceutical industry, Tris

Through the Helping to End Addiction Long-term® Initiative (NIH HEAL Initiative®), NIH has awarded grants to fund the optimization of new therapies to prevent and treat opioid use disorder (OUD).

Key Points: 
  • Through the Helping to End Addiction Long-term® Initiative (NIH HEAL Initiative®), NIH has awarded grants to fund the optimization of new therapies to prevent and treat opioid use disorder (OUD).
  • Cebranopadol is an investigational, dual nociception/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist.
  • Further, cebranopadol has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment for OUD.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Statement on Behalf of the Trustees of the Opioid Master Disbursement Trust II (the "Opioid MDT II")

Retrieved on: 
Wednesday, August 23, 2023
City, Trust, Opioid, Trustee, NAS, Bankruptcy, Security (finance), Cereal, Mallinckrodt

Given Mallinckrodt's downwards spiraling financial performance and the Opioid MDT II Trust's status as an unsecured creditor in a bankruptcy (in which approximately $3.5 billion in debt would be ahead of the Trust in priority), the Opioid MDT II Trustees believe this deal is the best possible outcome.

Key Points: 
  • Given Mallinckrodt's downwards spiraling financial performance and the Opioid MDT II Trust's status as an unsecured creditor in a bankruptcy (in which approximately $3.5 billion in debt would be ahead of the Trust in priority), the Opioid MDT II Trustees believe this deal is the best possible outcome.
  • The Opioid MDT II Trustees are very cognizant of the effects of the Opioid Crisis on states, cities, counties, tribes, individuals, babies born with NAS, and others.
  • This is a bittersweet result that the amounts that these victims will receive from Mallinckrodt have been substantially reduced.
  • However, given all that is known about other opioid pharmaceutical defendants, the certainty of receiving funds today rather than uncertain future payments is a priority."

Neuragenex Expands to Open New Illinois Location, Giving More People Access to its Innovative Approach to Chronic Pain Management

Retrieved on: 
Tuesday, August 8, 2023
Aurora, Heart, Communication, Travel, Diabetic neuropathy, Quality of life, Heroin, Opioid, Pain, Death, Abuse, Patient, Nervous system, Pain management, Wheaton, Health, Chronic pain, Poultry farming, Canal, Dentistry, Electroanalgesia

With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.

Key Points: 
  • With its groundbreaking approach to chronic pain management that is drug-free and non-invasive, Neuragenex is dedicated to becoming the largest and fastest growing chronic pain management practice in the United States.
  • Specializing in non-pharmaceutical and non-invasive pain management treatments, Neuragenex recognizes that traditional pain management approaches often rely on medications, surgeries, or therapies with limited efficacy.
  • Patients who have experienced Neuragenex's innovative approach to chronic pain management have reported remarkable success and transformative outcomes.
  • Committed to pushing the boundaries of pain management, Neuragenex continuously aims to provide relief and improve the lives of individuals suffering from persistent pain.